{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:41:19Z","timestamp":1782315679892,"version":"3.54.5"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunotherapy has become a mainstay of treatment for many cancers. Multiple immune checkpoint inhibitors have been used to treat malignancies, including anti-programed death-1 (PD1) and anti-cytotoxic T-lymphocyte-associated protein (anti-CTLA4). However, a significant percentage of patients develop resistance to these immunotherapy drugs. Therefore, novel strategies were developed to target other aspects of the immune response. Lymphocyte activation gene-3 (LAG-3) is a cell-surface molecule found on natural killer cells and activated T-cells which negatively regulates T-cell proliferation and function. LAG-3 inhibitors interact with LAG-3 ligands on the surface of T-cells to block T-regulatory (Treg) cell activity, suppress cytokine secretion and restore dysfunctional effector T-cells which subsequently attack and destroy cancer cells. This review reports the dermatologic side effects associated with LAG-3 inhibitors used in the treatment of melanomas. Using PRISMA 2022 guidelines, a comprehensive literature review of PubMed, Google Scholar, Embase, Cochrane, and Web of Science databases was conducted. Three studies were identified that demonstrated that the use of LAG-3 inhibitors, whether as a single agent or in combination with other immune checkpoint inhibitors, resulted in stomatitis, pruritus, rash, dry skin, erythema, and vitiligo. Further research is warranted to assess the cutaneous adverse events observed with LAG-3 inhibitors in treating melanoma and to identify populations most vulnerable to such side effects.<\/jats:p>","DOI":"10.1002\/ski2.296","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T10:50:47Z","timestamp":1697194247000},"source":"Crossref","is-referenced-by-count":4,"title":["Cutaneous Adverse Effects Associated with Lag-3 Inhibitor Use in Cancer Treatment: A Systematic Review"],"prefix":"10.1093","volume":"3","author":[{"given":"Hira","family":"Ghani","sequence":"first","affiliation":[{"name":"Nassau University Medical Center , East Meadow ,, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-616X","authenticated-orcid":false,"given":"Samavia","family":"Khan","sequence":"additional","affiliation":[{"name":"Center for Dermatology, Rutgers Robert Wood Johnson Medical School , Somerset ,, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Jamgochian","sequence":"additional","affiliation":[{"name":"Center for Dermatology, Rutgers Robert Wood Johnson Medical School , Somerset ,, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Richards","sequence":"additional","affiliation":[{"name":"Cooper Medical School of Rowan University , Camden ,, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"DeCecco","sequence":"additional","affiliation":[{"name":"Cooper Medical School of Rowan University , Camden ,, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Fliorent","sequence":"additional","affiliation":[{"name":"Rowan-Virtua School of Osteopathic Medicine , Stratford ,, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithisha","family":"Cheendalla","sequence":"additional","affiliation":[{"name":"Rowan-Virtua School of Osteopathic Medicine , Stratford ,, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Khatri","sequence":"additional","affiliation":[{"name":"Skin and Laser Surgery Center of New England , Nashua ,, New Hampshire ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babar","family":"Rao","sequence":"additional","affiliation":[{"name":"Center for Dermatology, Rutgers Robert Wood Johnson Medical School , Somerset ,, New Jersey ,","place":["USA"]},{"name":"Department of Dermatology, Weill Cornell Medicine , New York ,, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"issue":"4","key":"2025010818093448200_ski2296-bib-0001","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cps.2021.05.001","article-title":"Melanoma risk factors and prevention","volume":"48","author":"Dzwierzynski","year":"2021","journal-title":"Clin Plast Surg"},{"issue":"3","key":"2025010818093448200_ski2296-bib-0002","doi-asserted-by":"publisher","first-page":"300","DOI":"10.23736\/s2784-8671.21.06958-3","article-title":"Histopathologic classification and prognostic factors of melanoma: a 2021 update","volume":"156","author":"Bobos","year":"2021","journal-title":"Ital J Dermatol Venerol"},{"issue":"11","key":"2025010818093448200_ski2296-bib-0003","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"2025010818093448200_ski2296-bib-0004","doi-asserted-by":"publisher","DOI":"10.1177\/1534735421990078","article-title":"Current advancements and novel strategies in the treatment of metastatic melanoma","volume":"20","author":"Sood","year":"2021","journal-title":"Integr Cancer Ther"},{"issue":"1","key":"2025010818093448200_ski2296-bib-0005","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"2025010818093448200_ski2296-bib-0006","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025010818093448200_ski2296-bib-0007","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615317","article-title":"LAG3's Enigmatic mechanism of action","volume":"11","author":"Graydon","year":"2020","journal-title":"Front Immunol"},{"issue":"5-6","key":"2025010818093448200_ski2296-bib-0008","doi-asserted-by":"publisher","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"issue":"2","key":"2025010818093448200_ski2296-bib-0009","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003776","article-title":"Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","volume":"10","author":"Sch\u00f6ffski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2025010818093448200_ski2296-bib-0010","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10637-012-9866-y","article-title":"A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma","volume":"31","author":"Wang-Gillam","year":"2013","journal-title":"Invest New Drugs"},{"issue":"3","key":"2025010818093448200_ski2296-bib-0011","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors","volume":"19","author":"Sibaud","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"2025010818093448200_ski2296-bib-0012","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer"},{"issue":"Suppl 1","key":"2025010818093448200_ski2296-bib-0013","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40257-018-0384-3","article-title":"Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails","volume":"19","author":"Lacouture","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"2025010818093448200_ski2296-bib-0014","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1177\/1078155220970621","article-title":"Dermatological side effects of immunotherapy drugs and targeted cancer therapies: importance of dermatology and oncology collaboration","volume":"27","author":"\u00c7elik","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"2025010818093448200_ski2296-bib-0015","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s12094-018-1953-x","article-title":"Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology","volume":"21","author":"Gr\u00e1valos","year":"2018","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"2025010818093448200_ski2296-bib-0016","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"2025010818093448200_ski2296-bib-0017","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"2025010818093448200_ski2296-bib-0018","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/jco.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025010818093448200_ski2296-bib-0019","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2018","journal-title":"J Cutan Med Surg"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/3\/6\/ski2.296\/59727294\/skinhd_3_6_e296.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/3\/6\/ski2.296\/59727294\/skinhd_3_6_e296.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:09:41Z","timestamp":1736359781000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.296\/7755549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.296","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,10,13]]},"article-number":"ski2.296"}}